(EMAILWIRE.COM, July 24, 2018 ) The biomarkers market is segmented on the basis of product, type, application, disease indication, and region.

On the basis of product, the market is segmented into consumables, services, and software. The consumables segment is estimated to account for the largest share of the global market in 2016. The large share of this segment is primarily attributed to the lower price of consumables than that of screening and automation instruments.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownload.asp?id=43

On the basis of type, the market is segmented into safety, efficacy, and validation biomarkers. The efficacy biomarkers segment is further classified into predictive, surrogate, pharmacodynamic, and prognostic biomarkers. In 2016, the safety biomarkers segment is expected to account for the largest share of the market. However, the efficacy biomarkers segment is estimated to register the highest CAGR during the forecast period.

On the basis of application, the market is categorized into diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other applications (DNA fingerprinting, ecotoxicology, and forensics). The diagnostics segment is estimated to account for the largest share of the market in 2016. Factors such as increasing prevalence of cancer, increased awareness and acceptance of diagnostic tests, technologically developed biomarker products, and individualized treatments for cancer are driving the growth of this segment.

On the basis of disease indication, the biomarkers market is categorized into cancer, cardiovascular disorders, neurological disorders, immunological disorders, and others (renal disorders, urinal diseases, diabetes, and tuberculosis). The cancer segment is estimated to account for the largest share of the global market in 2016. Cancer forms the largest segment primarily due to the increasing prevalence of cancer globally and the growing application of biomarkers in cancer diagnostics.

Growth in the market is mainly driven by factors such as increasing diagnostic applications of biomarkers, increasing R&D funding for pharma and biotech companies, increasing number of CROs and low cost of clinical trials in developing countries, the high prevalence of cancer, and new initiatives for biomarker research. On the other hand, high capital investments and low cost-benefit ratio, poorly suited regulatory and reimbursement systems, and technical issues related to sample collection and storage are the major factors restraining the growth of this market.

The biomarkers market is dominated by established players such as QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), Merck Millipore (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and Enzo Biochem, Inc. (U.S.).

Stakeholders

Academic Research Institutes
Biomarkers Assays and Reagents Manufacturers, Vendors, and Distributors
Contract Research Organizations (CROs)
Diagnostics Companies
Market Research and Consulting Firms
Pharmaceutical Companies
Regulators
Payers

Read More: https://www.marketsandmarkets.com/Market-Reports/biomarkers-advanced-technologies-and-global-market-43.html